###begin article-title 0
###xml 39 41 39 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 78 80 78 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Activation of cytosolic phospholipase A2 in dorsal root ganglion neurons by Ca2+/calmodulin-dependent protein kinase II after peripheral nerve injury
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 305 307 305 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 312 313 312 313 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 471 473 471 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 568 570 568 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 704 706 704 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
Peripheral nerve injury leads to a persistent neuropathic pain state in which innocuous stimulation elicits pain behavior (tactile allodynia), but the underlying mechanisms have remained largely unknown. We have previously shown that spinal nerve injury induces the activation of cytosolic phospholipase A2 (cPLA2) in injured dorsal root ganglion (DRG) neurons that contribute to tactile allodynia. However, little is known about the signaling pathway that activates cPLA2 after nerve injury. In the present study, we sought to determine the mechanisms underlying cPLA2 activation in injured DRG neurons in an animal model of neuropathic pain, focusing on mitogen-activated protein kinases (MAPKs) and Ca2+/calmodulin-dependent protein kinase II (CaMKII).
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 193 195 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 398 400 398 400 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 471 473 471 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 586 588 586 588 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 725 727 725 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 792 793 792 793 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 798 801 798 801 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 853 856 853 856 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
Pharmacological inhibition of either p38 or extracellular signal-regulated kinase (ERK) in the injured DRG, which led to suppression of the development of tactile allodynia, did not affect cPLA2 phosphorylation and translocation after nerve injury. By contrast, a CaMKII inhibitor prevented the development and expression of nerve injury-induced tactile allodynia and reduced both the level of cPLA2 phosphorylation and the number of DRG neurons showing translocated cPLA2 in response to nerve injury. Applying ATP to cultured DRG neurons increased the level of both phosphorylated cPLA2 and CaMKII in the vicinity of the plasma membrane and caused physical association of these two proteins. In addition, ATP-stimulated cPLA2 and CaMKII phosphorylation were inhibited by both a selective P2X3R/P2X2+3R antagonist and a nonselective voltage-dependent Ca2+ channel (VDCC) blocker.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 79 81 79 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 153 156 153 156 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
These results suggest that CaMKII, but not MAPKs, has an important role in cPLA2 activation following peripheral nerve injury, probably through P2X3R/P2X2+3R and VDCCs in primary afferent neurons.
###end p 7
###begin title 8
Background
###end title 8
###begin p 9
###xml 349 351 349 351 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 356 357 356 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 364 366 364 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 396 398 396 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 450 452 450 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 565 566 565 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 583 585 583 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 910 911 910 911 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 912 913 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 951 952 951 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 953 954 953 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 974 976 974 976 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 983 987 983 987 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3 </sub>
###xml 1001 1002 1001 1002 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1007 1010 1007 1010 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 1088 1090 1088 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1117 1118 1117 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1159 1161 1159 1161 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1179 1180 1179 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1185 1188 1185 1188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
Peripheral nerve injury leads to a persistent neuropathic pain state in which innocuous stimulation elicits pain behavior (tactile allodynia). Effective therapy for this pain is lacking, and the underlying mechanisms have remained largely unknown. We have previously shown that spinal nerve injury induces the activation of cytosolic phospholipase A2 (cPLA2), a Ca2+-dependent subclass of the PLA2 family [1], in DRG neurons, and that inhibiting cPLA2 suppresses nerve injury-induced tactile allodynia, revealing a crucial role for this enzyme in neuropathic pain [2]. Activated cPLA2 hydrolyzes the sn-2 position of glycerophospholipids to release arachidonic acid and lysophospholipid, and subsequently generates lipid mediators such as prostaglandins, leukotrienes, platelet-activating factor and lysophosphatidic acid. These mediators have been reported to cause sensitization of primary afferent neurons [3-5] and to produce allodynic behaviors [6-9]. Activation of P2X3 and P2X2+3 receptors (P2X3R/P2X2+3R), ionotropic ATP receptor subtypes, is involved in nerve injury-induced cPLA2 activation in DRG neurons [2]; however, the mechanism underlying cPLA2 activation via P2X3R/P2X2+3R remains to be elucidated.
###end p 9
###begin p 10
###xml 22 24 22 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 116 119 116 119 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 167 169 167 169 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 328 330 328 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 331 333 331 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 338 340 338 340 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 461 463 461 463 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 532 534 532 534 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 657 659 657 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 660 662 660 662 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 855 857 855 857 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 897 899 897 899 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 900 902 900 902 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1081 1083 1081 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
The activation of cPLA2 is regulated by phosphorylation of serine residues in addition to a rise in intracellular Ca2+ concentration [10]. The catalytic domain of cPLA2 contains several phosphorylation sites, Ser505, Ser515 and Ser727, which have been reported to be phosphorylated by mitogen-activated protein kinases (MAPKs) [11-13], Ca2+/calmodulin-dependent protein kinase II (CaMKII) [14] and MAPK-interacting kinase 1 (MNK1) or a closely related isoform [15], respectively. Among these serine residues, phosphorylation of cPLA2 at Ser505 and Ser727 has been shown to be important for agonist-induced arachidonic acid release in mammalian cell models [11,15-17]. It is possible that the phosphorylation of these three serine residues may be interactive, because MNK1 is activated by MAPKs such as p38 and extracellular signal-regulated kinase (ERK) [18], and CaMKII modulates ERK activation [19,20]. Indeed, it has been recently shown that phosphorylation on Ser505 by ERK is dependent upon Ser515 phosphorylation via the activation of CaMKII in vascular smooth muscle cells [21].
###end p 10
###begin p 11
###xml 38 40 38 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1103 1105 1103 1105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1202 1204 1202 1204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 901 904 <span type="species:ncbi:31658">CFA</span>
Among protein kinases involved in cPLA2 activation described above, MAPKs and CaMKII are expressed in DRG neurons and have important roles in pain signaling. Nerve injury induces an increase in p38 and ERK phosphorylation in DRG neurons and injection of these inhibitors attenuates nerve injury-induced tactile allodynia [22], strongly suggesting that MAPK activation in primary afferent neurons participates in neuropathic pain after nerve injury. CaMKII, which is especially abundant in the nervous system, has been implicated in various neuronal functions, such as the synthesis and release of neurotransmitter, modulation of ion channels and receptors, gene expression and synaptic plasticity. Recently, it was reported that CaMKII is localized in small- and medium-diameter DRG neurons that are known to transmit nociceptive signals [23,24]. Intraplantar injection of complete Freund's adjuvant (CFA), a model of inflammatory pain, increases the expression of CaMKII in sensory neurons [24], and CaMKII activation regulates the activity of transient receptor potential vanilloid type 1 (TRPV1) [25,26]. Thus, it raises the possibility that peripheral nerve injury may induce the activation of cPLA2 via the phosphorylation of MAPKs and CaMKII in primary afferent neurons, but their roles remain to be determined.
###end p 11
###begin p 12
###xml 10 12 10 12 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 159 162 159 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 198 201 198 201 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 238 240 238 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 382 384 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 450 452 450 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 549 551 549 551 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 611 613 611 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 725 727 725 727 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
While cPLA2 is distributed throughout the cytoplasm in the normal condition, in response to a variety of extracellular stimuli, an increase in intracellular Ca2+ concentration promotes binding of Ca2+ to the C2 domain and then allows cPLA2 to translocate to the perinuclear region, including the nuclear envelope, Golgi apparatus and endoplasmic reticulum in non-neuronal cells [27-31]. By contrast, our previous study showed that phosphorylated cPLA2 translocates to the plasma membranes of injured DRG neurons. Therefore, the translocation of cPLA2 in DRG neurons seems to be unique, but the mechanism of cPLA2 translocation remains unknown. In the present study, we investigated the involvement of MAPKs and CaMKII in cPLA2 phosphorylation and translocation in DRG neurons following peripheral nerve injury using pharmacological and molecular approaches.
###end p 12
###begin title 13
Results
###end title 13
###begin title 14
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Inhibition of neither p38 nor ERK prevents the activation of cPLA2 after nerve injury
###end title 14
###begin p 15
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 312 314 312 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 366 368 366 368 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 571 572 571 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 703 705 703 705 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 717 719 717 719 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 904 906 904 906 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 916 918 916 918 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 937 939 937 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 970 972 970 972 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1146 1148 1146 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1203 1205 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1260 1262 1260 1262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1269 1270 1269 1270 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1401 1403 1401 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1415 1417 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1426 1428 1426 1428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1440 1442 1440 1442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2C</xref>
###xml 1702 1704 1702 1704 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 591 595 <span type="species:ncbi:10116">rats</span>
###xml 1327 1331 <span type="species:ncbi:10116">rats</span>
###xml 1387 1391 <span type="species:ncbi:10116">rats</span>
An injury to the L5 nerve caused an increase in the phosphorylation of p38 mainly in small-diameter DRG neurons (data not shown), as previously demonstrated [22]. Nerve injury also induced an increase in ERK phosphorylation in satellite glial cells, and to a lesser extent, in large-diameter DRG neurons (Figure 1B). To examine the involvement of ERK and p38 in cPLA2 activation in DRG neurons, we tested the effects of inhibitors for MAPK kinase (MEK, a kinase upstream of ERK) and p38 that were administered through a catheter whose tip was positioned near the L5 DRG [2]. Vehicle-treated rats with an L5 nerve injury displayed a marked decrease in paw withdrawal threshold after nerve injury (Figure 1A and Figure 2A). By contrast, U0126, a selective inhibitor of MEK, and SB203580, a potent inhibitor of p38, significantly suppressed the development of tactile allodynia, as previously demonstrated [22] (U0126, p < 0.001; SB203580, p < 0.001) (Figure 1A and Figure 2A). Whereas p38 phosphorylation in DRG neurons was not inhibited by SB203580 (data not shown), because SB203580 binds to the ATP pocket in p38 to inhibit its kinase activity [32], ERK phosphorylation was suppressed by U0126 (Figure 1B). However, on day 7, the levels of phosphorylated cPLA2 (p-cPLA2) in the ipsilateral DRGs of U0126- and SB203580-treated rats were not changed compared with that in vehicle-treated rats. (Figure 1B and Figure 1C, Figure 2B and Figure 2C). Similar results were obtained in immunohistochemical analyses using the ipsilateral L5 DRG that was removed 45-60 min after injection of these inhibitors (data not shown). These results indicate that p38 and ERK are not involved in nerve injury-induced cPLA2 activation in DRG neurons.
###end p 15
###begin p 16
###xml 43 45 43 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A MEK inhibitor U0126 does not prevent cPLA<sub>2 </sub>activation after nerve injury</bold>
###xml 279 281 277 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 292 294 290 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 343 345 341 343 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 491 493 489 491 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 558 562 <span type="species:ncbi:10116">rats</span>
A MEK inhibitor U0126 does not prevent cPLA2 activation after nerve injury. (A) Effect of U0126 on the development of nerve injury-induced tactile allodynia. Results are means +/- SEM of the paw withdrawal thresholds on the ipsilateral (ipsi) and contralateral (contra) sides. **p < 0.01, ***p < 0.001 compared with the threshold on day 0. ###p < 0.001 compared with the threshold of the vehicle-treated group. (B, C) Immunohistochemical (B) and western blot (C) analyses of p-ERK and p-cPLA2 proteins in the ipsilateral L5 DRG of vehicle- and U0126-treated rats 7 days after nerve injury. Scale bar, 50 mum.
###end p 16
###begin p 17
###xml 46 48 46 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A p38 inhibitor SB203580 does not prevent cPLA<sub>2 </sub>activation after nerve injury</bold>
###xml 286 288 284 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 337 339 335 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 475 477 473 475 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 544 548 <span type="species:ncbi:10116">rats</span>
A p38 inhibitor SB203580 does not prevent cPLA2 activation after nerve injury. (A) Effect of SB203580 on the development of nerve injury-induced tactile allodynia. Results are means +/- SEM of the paw withdrawal thresholds on the ipsilateral (ipsi) and contralateral (contra) sides. ***p < 0.001 compared with the threshold on day 0. ###p < 0.001 compared with the threshold of the vehicle-treated group. (B, C) Immunohistochemical (B) and western blot (C) analyses of p-cPLA2 protein in the ipsilateral L5 DRG of vehicle- and SB203580-treated rats 7 days after nerve injury. Scale bar, 50 mum.
###end p 17
###begin title 18
Peripheral nerve injury induces CaMKII activation in primary afferent neurons
###end title 18
###begin p 19
###xml 320 322 320 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 399 401 399 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 162 166 <span type="species:ncbi:10116">rats</span>
To examine whether spinal nerve injury induces the activation of CaMKII in DRG neurons, we performed immunohistochemical analysis using the DRGs of nerve-injured rats. We found that L5 nerve injury caused an increase in the level of phosphorylated CaMKII-immunoreactivity (p-CaMKII-IR) in the ipsilateral L5 DRG (Figure 3A). Accumulated p-CaMKII-IR was not observed in the contralateral DRG (Figure 3A). At the subcellular level, p-CaMKII-IR in damaged DRG neurons was accumulated at the edges of the area immunostained with the neuronal marker microtubule-associated protein 2 (MAP2) (Figure 3B).
###end p 19
###begin p 20
###xml 0 53 0 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">CaMKII is activated in DRG neurons after nerve injury</bold>
CaMKII is activated in DRG neurons after nerve injury. (A) Immunohistochemical analysis of p-CaMKII protein in the L5 DRG 7 days after nerve injury. (B) Double immunofluorescence labeling of p-CaMKII with MAP2, a marker of neurons, in the ipsilateral L5 DRG 7 days after nerve injury. Scale bar, 50 mum.
###end p 20
###begin title 21
###xml 55 57 55 57 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
A CaMKII inhibitor suppresses nerve injury-induced cPLA2 activation
###end title 21
###begin p 22
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 98 107 98 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 152 154 152 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 276 278 276 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 381 383 381 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 617 619 617 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 782 784 782 784 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 953 955 953 955 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 1071 1073 1071 1073 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4C</xref>
###xml 1174 1176 1174 1176 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1205 1207 1205 1207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1233 1235 1233 1235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 1265 1267 1265 1267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4D</xref>
###xml 1296 1298 1296 1298 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 1372 1374 1370 1372 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1536 1538 1534 1536 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1553 1555 1551 1553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1572 1574 1570 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4E</xref>
###xml 1719 1721 1717 1719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1738 1740 1736 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4F</xref>
###xml 459 465 <span type="species:ncbi:9986">rabbit</span>
###xml 895 899 <span type="species:ncbi:10116">rats</span>
###xml 995 999 <span type="species:ncbi:10116">rats</span>
###xml 1044 1048 <span type="species:ncbi:10116">rats</span>
Recent evidence has indicated that CaMKII plays an important role in the phosphorylation of cPLA2 in vitro [14,21], suggesting a role for CaMKII in cPLA2 phosphorylation in injured DRG neurons. To investigate this hypothesis, we examined co-localization of phosphorylated cPLA2 and CaMKII in DRG neurons. Since it is difficult to perform double-immunolabeling of tissue with p-cPLA2 and p-CaMKII antibodies, because they were raised in the same host species (rabbit), we used two adjacent DRG sections and singly immunostained one section with each antibody. We observed DRG neurons that were positive for both p-cPLA2 and p-CaMKII in the injured DRG (indicated by arrowheads, Figure 4A). To further test whether the inhibition of CaMKII activation affects nerve injury-induced cPLA2 activation, we injected a CaMKII inhibitor, KN-93, and a negative control for KN-93, KN-92, into nerve-injured rats. We found that the levels of both p-CaMKII and p-cPLA2 in the ipsilateral DRG of KN-93-treated rats were much lower than those in KN-92-treated rats (Figure 4B and Figure 4C), and administration of KN-93 markedly reduced the number of DRG neurons showing translocated p-cPLA2 in response to nerve injury (p < 0.001) on day 7 (Figure 4D) compared with KN-92 (Figure 4D) or vehicle administration (n = 2, 38.3 +/- 0.3%). These results suggest that CaMKII is involved in cPLA2 phosphorylation and translocation in DRG neurons caused by nerve injury. In addition, KN-93 significantly suppressed the development of tactile allodynia (day 3: p < 0.01, day 7: p < 0.001) (Figure 4E) and a single administration of KN-93 near the DRG 7 days after nerve injury also significantly suppressed the expression of tactile allodynia (p < 0.001) (Figure 4F). No alteration in motor behavior after KN-93 treatment was observed (data not shown). Taken together, these results indicate that inhibiting CaMKII activation prevents the development and expression of nerve injury-induced tactile allodynia.
###end p 22
###begin p 23
###xml 62 64 62 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 74 0 74 <bold xmlns:xlink="http://www.w3.org/1999/xlink">A CaMKII inhibitor KN-93 suppresses tactile allodynia and cPLA<sub>2 </sub>activation</bold>
###xml 161 163 161 163 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 323 324 323 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 369 370 368 369 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 599 600 596 597 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 629 631 626 628 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 684 686 681 683 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 937 939 932 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 987 989 982 984 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1000 1002 995 997 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1202 1204 1195 1197 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1256 1258 1249 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 226 230 <span type="species:ncbi:10116">rats</span>
###xml 530 534 <span type="species:ncbi:10116">rats</span>
A CaMKII inhibitor KN-93 suppresses tactile allodynia and cPLA2 activation. (A-C) Immunohistochemical (A, B) and western blot (C) analyses of p-CaMKII and p-cPLA2 proteins in the ipsilateral L5 DRG of KN-92- and KN-93-treated rats 7 days after nerve injury. Arrowheads show DRG neurons positive for both p-CaMKII and p-cPLA2. Scale bar, 50 mum. (D) The number of p-cPLA2-translocated neurons in the ipsilateral L5 DRG 7 days after nerve injury. About 1000 neurons profiles were counted in twenty randomly chosen sections from six rats in each group. Results are percentages (means +/- SEM) of p-cPLA2-translocated neurons (p-cPLA2 neurons) relative to the total number of neurons. ***p < 0.001 compared with the KN-92-treated group. (E) Effect of KN-93 on the development of nerve injury-induced tactile allodynia. Results are means +/- SEM of the paw withdrawal thresholds on the ipsilateral (ipsi) and contralateral (contra) sides. ***p < 0.001 compared with the threshold on day 0. ##p < 0.01, ###p < 0.001 compared with the threshold of the KN-92-treated group. (F) Effect of a single administration of KN-93 on the decrease in paw withdrawal threshold (mean +/- SEM) 7 days after nerve injury. ***p < 0.001 compared with pre-injury baseline (Pre). ###p < 0.001 compared with the threshold on day 7.
###end p 23
###begin title 24
ATP receptor-dependent activation of CaMKII in cultured primary sensory neurons
###end title 24
###begin p 25
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 26 27 26 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 32 35 32 35 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 327 329 327 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 434 435 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 542 544 542 544 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 596 598 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 670 671 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 680 681 666 667 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 721 723 707 709 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 751 753 737 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6A</xref>
###xml 854 855 840 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 860 863 846 849 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 928 930 914 916 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 978 980 964 966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6B</xref>
###xml 1040 1043 1026 1029 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1092 1095 1078 1081 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1190 1192 1176 1178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1232 1234 1218 1220 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1340 1342 1319 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6C</xref>
###xml 1550 1552 1529 1531 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1560 1562 1539 1541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6D</xref>
###xml 1596 1597 1575 1576 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 1602 1605 1581 1584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 1645 1647 1624 1626 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1685 1687 1664 1666 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
cPLA2 is activated via P2X3R/P2X2+3R in DRG neurons after nerve injury [2]. To examine whether CaMKII is also activated by these receptors, we applied ATP to cultured DRG neurons and found that the level of p-CaMKII-IR was increased in the vicinity of the plasma membranes of DRG neurons, similar to the translocation of p-cPLA2 after applying ATP (Figure 5A). Next, to investigate the physical association between p-CaMKII and p-cPLA2, we performed immunoprecipitation experiments and found that p-CaMKII was coimmunoprecipitated with p-cPLA2 in DRG neurons after the application of ATP (Figure 5B). Applying alpha,beta-methylene ATP (alphabetameATP), an agonist of P2X1- and P2X3-containing P2XRs, also increased p-cPLA2 and p-CaMKII levels (Figure 6A). When DRG neurons were pre-treated with KN-93 or A-317491, a potent and selective antagonist of P2X3R/P2X2+3R, prior to applying ATP, the ATP-induced phosphorylation of cPLA2 and CaMKII were significantly inhibited (Figure 6B). We also examined the contribution of voltage-dependent Ca2+ channels (VDCCs) to CaMKII activation, because Ca2+ influx via VDCCs has been reported to also be involved in CaMKII activation in neuronal cells [33]. The increases in the levels of p-cPLA2 and p-CaMKII induced by alphabetameATP were abolished by cadmium, a nonselective blocker of VDCCs (Figure 6C). Furthermore, applying BayK8644, an agonist for VDCCs, to primary DRG neurons increased the level of p-CaMKII-IR in the vicinity of the plasma membranes of DRG neurons and caused the translocation of p-cPLA2 (Figure 6D). These results indicate that P2X3R/P2X2+3R and VDCCs have important roles in cPLA2 and CaMKII activation, and that p-cPLA2 is translocated to the plasma membranes of DRG neurons as a result of its interaction with p-CaMKII.
###end p 25
###begin p 26
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">cPLA<sub>2 </sub>and CaMKII are activated in the plasma membrane after applying ATP</bold>
###xml 110 112 110 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 393 395 391 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 515 517 512 514 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 615 617 612 614 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
cPLA2 and CaMKII are activated in the plasma membrane after applying ATP. (A) Increase in the levels of p-cPLA2 and p-CaMKII immunofluorescence and translocation of these proteins to the plasma membrane in neurons 5 min after the application of 10 muM ATP compared with controls. Similar results were observed in each of three experiments. Scale bar, 20 mum. (B) The association between p-cPLA2 and p-CaMKII after application of 10 muM ATP. Protein samples were subjected to immunoprecipitation with the anti-p-cPLA2 antibody, and isolated complex was separated by electrophoresis and immunoblotted with anti-p-cPLA2 and anti-p-CaMKII antibodies.
###end p 26
###begin p 27
###xml 4 6 4 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 53 55 53 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3 </sub>
###xml 62 66 62 66 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3 </sub>
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">cPLA<sub>2 </sub>and CaMKII are activated via stimulation of P2X<sub>3 </sub>and P2X<sub>2+3 </sub>receptors in primary DRG neurons</bold>
###xml 137 139 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 448 450 420 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 579 581 551 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 669 671 641 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 713 715 685 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 756 758 728 730 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 860 862 825 827 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 228 231 <span type="species:ncbi:10116">rat</span>
cPLA2 and CaMKII are activated via stimulation of P2X3 and P2X2+3 receptors in primary DRG neurons. (A-C) Western blot analyses of p-cPLA2 and p-CaMKII proteins after applying ATP or alpha,beta-methylene ATP (alphabetameATP) to rat primary DRG neurons. The primary DRG culture was incubated with ATP or alphabetameATP. KN-92, KN-93, A-317491 or cadmium was added to the neurons 10 min before the application of ATP or alphabetameATP. The total cPLA2 and CaMKII proteins loaded on each lane were also detected as loading controls. The bar graphs show the relative values of p-cPLA2 and p-CaMKII proteins induction with respect to controls, after normalizing for the cPLA2 and CaMKII protein levels, respectively. *p < 0.05 compared with the control group. #p < 0.05 compared with the ATP- or alphabetameATP-stimulated group. (D) Increase in the levels of p-cPLA2 and p-CaMKII immunofluorescence and translocation of these proteins to the plasma membrane in neurons 5 min after the application of 10 muM BayK8644 compared with controls. Scale bar, 20 mum.
###end p 27
###begin title 28
Discussion
###end title 28
###begin p 29
###xml 119 121 119 121 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
In the present study, we demonstrated for the first time that activation of CaMKII in DRG neurons is important for cPLA2 phosphorylation and translocation as well as the development and maintenance of neuropathic pain after peripheral nerve injury.
###end p 29
###begin p 30
###xml 73 75 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 167 169 167 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 329 330 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 495 496 495 496 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 552 554 552 554 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 709 711 709 711 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 771 772 771 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 850 851 850 851 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1011 1012 1011 1012 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1013 1014 1013 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1149 1150 1149 1150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
p38 and ERK have been shown to be involved in the phosphorylation of cPLA2 in non-neuronal cells [11-13] and to be activated in DRG neurons after spinal nerve injury [22]. Although p38 and MEK inhibitors administered near the injured DRG prevented the development of tactile allodynia, these did not affect the activation of cPLA2. It is thus conceivable that p38 and ERK in DRG neurons participate in the development of tactile allodynia through an independent pathway or downstream of the cPLA2-mediated signaling pathway. In particular, ERK and cPLA2 are activated in different types of cells in the injured DRG: ERK phosphorylation was seen predominantly in satellite glial cells, while activation of cPLA2 is observed mainly in medium-to-large-diameter DRG neurons [2], which supports our hypothesis. Alternatively, it is also possible that cPLA2-mediated lipid mediators, such as prostaglandins, platelet-activating factor and lysophosphatidic acid, which have been reported to produce tactile allodynia [6-9], may affect the excitation of DRG neurons via MAPK activation in primary afferent neurons. Studies in our laboratory determining cPLA2-mediated products and their roles in neuropathic pain are currently underway.
###end p 30
###begin p 31
###xml 35 37 35 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 65 74 65 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 78 80 78 80 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 264 266 264 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 267 269 267 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 377 379 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 380 382 380 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 502 504 502 504 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 957 959 957 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1009 1011 1009 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 1116 1118 1116 1118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1439 1441 1439 1441 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1571 1573 1571 1573 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1743 1745 1743 1745 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2053 2055 2053 2055 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2066 2067 2066 2067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 2232 2234 2232 2234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 388 391 <span type="species:ncbi:31658">CFA</span>
Recently, it was reported that cPLA2 is phosphorylated by CaMKII in vitro [14,21]. CaMKII is preferentially localized in pain-processing regions in the nervous system, such as the superficial laminae of the dorsal horn in the spinal cord and dorsal root ganglion [23,24]. CaMKII activity is significantly increased in the spinal cord after injection of capsaicin and formalin [34,35] and CFA-induced pain behaviors and increase of CaMKII phosphorylation in the spinal dorsal horn are reduced by KN-93 [36]. Furthermore, intrathecal injection of KN-93 attenuates the development of thermal hyperalgesia and mechanical allodynia following chronic constriction injury (CCI) [37]. These findings suggest that CaMKII expressed in the spinal cord contributes to chronic inflammatory and neuropathic pain as well as acute pain. By contrast, in DRG neurons, the phosphorylation of CaMKII has an important role in nerve growth factor-induced sensitization of TRPV1 [25] and modulation of the agonist binding to TRPV1 [26]. CaMKII expression in sensory neurons has been shown to be increased during chronic inflammation pain [24], but there have been no reports investigating the role of CaMKII in DRG neurons in neuropathic pain. In our immunohistochemical analyses, the level of CaMKII phosphorylation was increased in the ipsilateral DRG neurons after nerve injury. We also found that DRG neurons showing translocation of both phosphorylated cPLA2 and CaMKII to the plasma membrane were observed in the injured DRG. Importantly, pharmacological blockade of CaMKII prevented cPLA2 phosphorylation and translocation as well as tactile allodynia following peripheral nerve injury. These results suggest that the phosphorylation and translocation of cPLA2 to the plasma membrane via an interaction with activated CaMKII is a key event in the development of nerve injury-induced tactile allodynia. Our present behavioral study also reveals that KN-93 is effective in treating existing tactile allodynia, which is consistent with the behavioral analysis using a cPLA2 inhibitor [2]. Considering a previous result showing that KN-93 administered near the spinal cord 7 days after CCI produces no significant effect on existing tactile allodynia [37], the role of CaMKII in the maintenance phase of neuropathic pain may be predominant in the DRG rather than in the spinal cord.
###end p 31
###begin p 32
###xml 73 75 73 75 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 260 262 260 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 315 316 315 316 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 321 324 321 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 449 451 449 451 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 452 454 452 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 484 487 484 487 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 519 520 519 520 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 525 528 525 528 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 669 670 669 670 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 675 678 675 678 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 762 764 762 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 874 876 874 876 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 964 965 964 965 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1174 1177 1174 1177 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1260 1262 1260 1262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1368 1370 1368 1370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1550 1552 1550 1552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1553 1555 1553 1555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1766 1768 1766 1768 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 2018 2019 2018 2019 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2065 2067 2065 2067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 2110 2112 2110 2112 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2159 2160 2159 2160 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2165 2168 2165 2168 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 2214 2215 2214 2215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 2220 2223 2220 2223 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 2253 2255 2253 2255 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Applying ATP caused an increase in the levels of both phosphorylated cPLA2 and CaMKII in the vicinity of the plasma membrane, and physical association of these two proteins in primary cultured DRG neurons. ATP receptor agonist-dependent phosphorylation of cPLA2 and CaMKII were inhibited either by the selective P2X3R/P2X2+3R antagonist A-317491 or by the nonselective VDCC blocker cadmium. Because the ATP-evoked current is not blocked by cadmium [38,39], our results suggest that Ca2+ influx via the activation of P2X3R/P2X2+3R may not be enough to activate CaMKII and that VDCC activation (presumably resulting from a depolarization of DRG neurons by stimulating P2X3R/P2X2+3R) may contribute to CaMKII activation in DRG neurons. Activation of CaMKII and cPLA2 in A23187-stimulated DRG neurons supports this notion. Subsequently, activated CaMKII would phosphorylate cPLA2 and be translocated to the plasma membrane by interacting physically with activated cPLA2. To date, there have been many studies investigating CaMKII translocation and its roles in synaptic transmission and plasticity in the central nervous system. In hippocampal neurons, CaMKII is activated by Ca2+ influx through NMDA receptors and then translocated to postsynaptic density (PSD) [40] in parallel with sustained CaMKII activity owing to an interaction with the NMDA receptor subunit NR2B [41]. Activated CaMKII subsequently phosphorylates many PSD proteins, including AMPA receptors, and binds to NMDA receptor subunits, resulting in induction of long-term potentiation [42,43]. In relation to pain, a previous study has reported that inhibition of CaMKII activity blocks translocation of AMPA receptor subunits to the plasma membrane of spinal cord neurons after capsaicin stimulation [44]. Although there have been few reports investigating the translocation of CaMKII in the peripheral nervous system, a recent study demonstrated that CaMKII activated by electric stimulation of the sciatic nerve is implicated in the trafficking of P2X3R toward the plasma membranes of DRG neurons [45]. Given the present data showing that cPLA2 and CaMKII are activated via stimulation of P2X3R/P2X2+3R in DRG neurons, this work indicates that P2X3R/P2X2+3R-dependent activation of cPLA2 and CaMKII is enhanced under pathological conditions, such as neuropathic pain.
###end p 32
###begin title 33
Conclusion
###end title 33
###begin p 34
###xml 88 89 88 89 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 217 218 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 223 226 223 226 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2+3</sub>
###xml 252 255 252 255 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 450 452 450 452 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 481 483 481 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The present study demonstrated that CaMKII, but not MAPKs, has an important role in cPLA2-dependent tactile allodynia via the regulation of phosphorylation and translocation of cPLA2, both of which are mediated by P2X3R/P2X2+3R and voltage-dependent Ca2+ channels in primary afferent neurons following peripheral nerve injury. Our results provide important evidence to help us to understand the mechanism underlying neuropathic pain modulated by cPLA2 and the translocation of cPLA2 and CaMKII in DRG neurons under pathophysiological conditions.
###end p 34
###begin title 35
Methods
###end title 35
###begin title 36
Animals
###end title 36
###begin p 37
###xml 5 16 <span type="species:ncbi:10116">Wistar rats</span>
Male Wistar rats (250-300 g) were used. Animals were housed at a temperature of 22 +/- 1degreesC with a 12-h light-dark cycle (light on 8:30 to 20:30), and fed food and water ad libitum. All of the animals used in the present study were obtained, housed, cared for and used in accordance with the guidelines of Kyushu University.
###end p 37
###begin title 38
Neuropathic pain model
###end title 38
###begin p 39
###xml 39 41 39 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 68 70 68 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 379 381 379 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 81 92 <span type="species:ncbi:10116">Wistar rats</span>
We used the spinal nerve injury model [46] with some modifications [47]: in male Wistar rats a unilateral L5 spinal nerve was tightly ligated and cut just distal to the ligature. The mechanical allodynia was assessed by using calibrated von Frey filaments (0.4-15.1 g, Stoelting, Wood Dale, Illinois, USA) and the paw withdrawal threshold was determined as described previously [47].
###end p 39
###begin title 40
Drug treatment
###end title 40
###begin p 41
###xml 332 333 332 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1012 1014 1007 1009 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 433 437 <span type="species:ncbi:10116">Rats</span>
Rats were implanted with catheters for intrathecal injection according to the method described previously. Under isoflurane anesthesia, a sterile 32 gauge intrathecal catheter (ReCathCo, Allison Park, Pennsylvannia, USA) was inserted through the atlanto-occipital membrane and to the L4 or L5 DRG and externalized through the skin [2]. After the experiments, we confirmed that the tip of the catheter was positioned near the L5 DRG. Rats were injected intrathecally with each drug using a 25 mul Hamilton syringe with a 30-gauge needle once a day from day 0 (just before the nerve injury) to day 6. The drugs used in this study are listed below: SB203580 (30 nmol/10 mul, Calbiochem, San Diego, California, USA), U0126 (10 nmol/10 mul, Promega, Madison, Wisconsin, USA), KN-92 (10 nmol/10 mul, Calbiochem) and KN-93 (10 nmol/10 mul, Calbiochem). The paw withdrawal threshold was tested 21-24 hr after the injection of each drug at 1, 3, 7 days post-injury. After the test on day 7, to examine the level of p-cPLA2 in injured DRG neurons in vehicle- and inhibitor-treated groups using immunohistochemistry and western blotting, the L5 DRG ipsilateral to the nerve injury was removed. For the experiment in which the effect of a single administration of KN-93 on the established allodynia was examined on day 7 after nerve injury, behavioral test was performed immediately before and after the injection of KN-93 (10 nmol/10 mul).
###end p 41
###begin title 42
Immunohistochemistry
###end title 42
###begin p 43
###xml 505 507 498 500 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 519 520 512 513 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1123 1124 1116 1117 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1246 1247 1239 1240 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 314 318 <span type="species:ncbi:9925">goat</span>
###xml 857 863 <span type="species:ncbi:9986">rabbit</span>
###xml 922 927 <span type="species:ncbi:10090">mouse</span>
###xml 1363 1367 <span type="species:ncbi:10116">rats</span>
Rats were deeply anesthetized by pentobarbital (100 mg/kg, i.p.) and perfused transcardially with 4% paraformaldehyde. DRG sections were removed, postfixed with the same fixative, and placed in 30% sucrose solution for 24 hr at 4degreesC. The DRG sections (15 mum) were incubated in a blocking solution [3% normal goat serum/0.3% Triton X-100/phosphate-buffered saline (PBS) (-) ] and then with anti-phospho-ERK (anti-p-ERK) antibody (1:500, Cell Signaling, Beverly, Massachusetts, USA), anti-phospho-cPLA2 (anti-p-cPLA2) antibody (1:200, Abcam, Cambridge, Massachusetts, USA) or anti-phospho-CaMKII (anti-p-CaMKII) antibody (1:500, Promega). Identification of the type of p-CaMKII-translocated cells was performed with MAP2, a marker of neurons (1:1000, Chemicon, Temecula, California, USA). Following incubation, the DRG sections were incubated with anti-rabbit immunoglobulin G (IgG)-conjugated Alexa Fluor 488 or anti-mouse IgG-conjugated Alexa Fluor 546 (1:1000, Molecular Probes, Eugene, Oregon, USA). The sections were then analyzed by a confocal microscope (LSM510, Zeiss, Oberkochen, Germany). The number of p-cPLA2-IR DRG neurons with translocation was counted in the L5 DRG ipsilateral to the nerve injury. The proportion of the p-cPLA2-translocated neurons to the total number of DRG neurons was determined in twenty randomly chosen sections from six rats in KN-92- and KN-93-treated groups.
###end p 43
###begin title 44
Western blotting
###end title 44
###begin p 45
###xml 343 345 343 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 1000 1002 988 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1046 1048 1034 1036 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 4 <span type="species:ncbi:10116">Rats</span>
###xml 1134 1145 <span type="species:ncbi:3704">horseradish</span>
###xml 1173 1179 <span type="species:ncbi:9986">rabbit</span>
Rats were deeply anesthetized by pentobarbital (100 mg/kg, i.p.) and the L5 DRG ipsilateral to the nerve injury was quickly removed. The tissue was then homogenized in homogenization buffer (20 mM Tris-Hcl pH 7.4, 2 mM EDTA, 0.5 mM EGTA, 0.32 M sucrose, protease and phosphatase inhibitors cocktails) for 10 s on ice and centrifuged at 1000 x g for 5 min at 4degreesC to remove cell debris. The supernatant was transferred to a new tube, mixed with Laemmli sample buffer (125 mM Tris-HCl pH 7.4, 20% glycerol, 4% (w/v) sodium dodecyl sulfate (SDS), 0.025% (w/v) bromophenol blue and 5% 2-mercaptoethanol), and boiled at 95degreesC for 5 min. All samples were subjected to BCA assay to adjust the loading protein amount before adding the Laemmli sample buffer. The samples were subjected to a 7.5% polyacrylamide gel (BioRad, Hercules, CA, USA), and the proteins were transferred electrophoretically to polyvinylidene difluoride membranes. After blocking, the membranes were incubated with anti-p-cPLA2 antibody (1:1000, Cell Signaling), anti-cPLA2 antibody (1:1000, Cell Signaling) overnight at 4degreesC and then were incubated with horseradish peroxidase-conjugated anti-rabbit IgG antibody (1:1000, Amersham Biosciences, Buckinghamshire, UK). The blots were detected using a chemiluminescence method (ECL system; Amersham Biosciences).
###end p 45
###begin title 46
###xml 11 14 <span type="species:ncbi:10116">rat</span>
Culture of rat primary DRG neurons
###end title 46
###begin p 47
###xml 784 785 775 776 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 55 66 <span type="species:ncbi:10116">Wistar rats</span>
###xml 452 457 <span type="species:ncbi:9796">horse</span>
###xml 575 580 <span type="species:ncbi:9606">human</span>
###xml 908 913 <span type="species:ncbi:9796">horse</span>
###xml 945 950 <span type="species:ncbi:9606">human</span>
The lumber DRGs (L1-6 segments) were removed from male Wistar rats and were treated in Dulbecco's modified eagle medium with 20 U/ml papain and 2 mg/ml collagenase type II for 1 hr at 37degreesC. At the end of this treatment the enzyme solution was removed and the DRGs were mechanically dissociated by trituration through a Pasteur pipette in Dulbecco's modified eagle medium. They were suspended in F-12 Nutrient Mixture liquid supplemented with 10% horse serum, 2 mM glutamine, 100 units/ml penicillin, 100 mug/ml streptomycin, 100 ng/ml nerve growth factor and 100 ng/ml human glial cell-line derived neurotrophic factor. They were plated in slide glasses or tissue culture dishes coated with 100 mug/ml poly-L-lysine and 10 mug/ml laminin and maintained in an atmosphere of 5% CO2/95% ambient air at 37degreesC for 72 hr. Following incubation, the medium was removed, replaced with fresh medium without horse serum, nerve growth factor and human glial cell-line derived neurotrophic factor, and further cultured at 37degreesC for an additional 24 hr.
###end p 47
###begin p 48
###xml 436 438 436 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
DRG neurons were incubated with ATP for 5 min, and KN-92, KN-93, A-317491 (Sigma, St Louis, MO, USA) or cadmium (Sigma) was added to the neurons 10 min before the application of ATP. After these treatments, the medium was removed and the cultures were scraped into RIPA buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.1% (w/v) SDS, 0.5% deoxycholate, protease and phosphatase inhibitors cocktails) and centrifuged at 21,600 x g for 30 min at 4degreesC to remove cell debris. The supernatant was transferred to a new tube, mixed with Laemmli sample buffer and boiled at 95degreesC for 5 min. Western blotting was carried out as described above. We used anti-p-CaMKII antibody (1:1000, Promega) or anti-CaMKII antibody (1:1000, Calbiochem) as additional primary antibodies.
###end p 48
###begin p 49
###xml 210 212 210 212 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 313 319 <span type="species:ncbi:9986">rabbit</span>
Immunocytochemistry was performed as follows. Immediately after treatment with ATP or BayK8644 (Sigma) for 5 min, cells were fixed with 3.7% formaldehyde. After blocking, neurons were incubated with anti-p-cPLA2 antibody (1:200, Abcam) or anti-p-CaMKII antibody (1:500, Promega) and then were incubated with anti-rabbit IgG-conjugated Alexa Fluor 488 (1:1000, Molecular Probes) followed by analysis with an LSM510 Imaging System (Zeiss).
###end p 49
###begin title 50
Immunoprecipitation
###end title 50
###begin p 51
###xml 309 311 309 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">g </italic>
###xml 547 549 541 543 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 415 421 <span type="species:ncbi:9986">rabbit</span>
###xml 610 616 <span type="species:ncbi:9986">rabbit</span>
###xml 997 1003 <span type="species:ncbi:9986">Rabbit</span>
###xml 1013 1024 <span type="species:ncbi:3704">horseradish</span>
###xml 1041 1047 <span type="species:ncbi:9986">rabbit</span>
Immediately after treatment with ATP for 5 min, cultured DRG neurons were rinsed once with PBS (-). RIPA buffer was added to each plate and plates were incubated on ice for 30 min. The cultured cells were scraped off and sonicated on ice three times for 5 s each. Protein samples were centrifuged at 21,600 x g for 30 min at 4degreesC and then the supernatants were transferred to a new tube, preabsorbed with anti-rabbit IgG beads (eBioscience, San Diego, California, USA) for 3 hr. The precleared protein extracts were incubated with anti-p-cPLA2 antibody (1:50, Cell Signaling) overnight at 4degreesC. Anti-rabbit IgG beads were subsequently added to the samples, and the mixture was further incubated for 1hr at 4degreesC. The protein beads complexes were washed four times with lysis buffer (50 mM Tris-HCl pH 8.0, 150 mM NaCl, 1% NP-40), and proteins were eluted by boiling for 10 min in Laemmli buffer. Samples were probed by western blotting using the corresponding primary antibodies and Rabbit TrueBlot-horseradish peroxidase anti-rabbit IgG (1:1000, eBioscience) as a secondary antibody. The blots were detected using a chemiluminescence method (ECL system).
###end p 51
###begin title 52
Statistical analysis
###end title 52
###begin p 53
###xml 127 129 125 127 <italic xmlns:xlink="http://www.w3.org/1999/xlink">t </italic>
###xml 148 150 146 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 204 213 202 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">post hoc </italic>
###xml 222 224 220 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
All data are presented as means +/- SEM. The statistical significance of difference between values was determined by Student's t test, Mann-Whitney U test or analysis of variance (ANOVA) with appropriate post hoc tests. A p value less than 0.05 was considered to be statistically significant.
###end p 53
###begin title 54
Competing interests
###end title 54
###begin p 55
The authors declare that they have no competing interests.
###end p 55
###begin title 56
Authors' contributions
###end title 56
###begin p 57
SH participated in the design of the study, carried out all experiments, performed the statistical analysis and wrote the manuscript. YK performed the part of the behavioral test and immunohistochemical staining. MT participated in designing the study and wrote the manuscript. KI supervised the experiments and wrote the manuscript. All authors read and approved the final manuscript.
###end p 57
###begin title 58
Acknowledgements
###end title 58
###begin p 59
This work was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (to MT, KI).
###end p 59
###begin article-title 60
Cytosolic phospholipase A2: biochemical properties and physiological roles
###end article-title 60
###begin article-title 61
P2X receptors-mediated cytosolic phospholipase A2 activation in primary afferent sensory neurons contributes to neuropathic pain
###end article-title 61
###begin article-title 62
Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances
###end article-title 62
###begin article-title 63
Bradykinin-12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia
###end article-title 63
###begin article-title 64
Lipid mediators of sensitivity in sensory neurons
###end article-title 64
###begin article-title 65
###xml 86 90 <span type="species:ncbi:10090">mice</span>
Allodynia evoked by intrathecal administration of prostaglandin F2 alpha to conscious mice
###end article-title 65
###begin article-title 66
###xml 80 84 <span type="species:ncbi:10090">mice</span>
Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice
###end article-title 66
###begin article-title 67
Initiation of neuropathic pain requires lysophosphatidic acid receptor signaling
###end article-title 67
###begin article-title 68
###xml 118 122 <span type="species:ncbi:10090">mice</span>
Development of tactile allodynia and thermal hyperalgesia by intrathecally administered platelet-activating factor in mice
###end article-title 68
###begin article-title 69
Regulatory mechanism and physiological role of cytosolic phospholipase A2
###end article-title 69
###begin article-title 70
cPLA2 is phosphorylated and activated by MAP kinase
###end article-title 70
###begin article-title 71
Phosphorylation and activation of a high molecular weight form of phospholipase A2 by p42 microtubule-associated protein 2 kinase and protein kinase C
###end article-title 71
###begin article-title 72
p38 mitogen-activated protein kinase phosphorylates cytosolic phospholipase A2 (cPLA2) in thrombin-stimulated platelets. Evidence that proline-directed phosphorylation is not required for mobilization of arachidonic acid by cPLA2
###end article-title 72
###begin article-title 73
Functional interaction of calcium-/calmodulin-dependent protein kinase II and cytosolic phospholipase A(2)
###end article-title 73
###begin article-title 74
Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases
###end article-title 74
###begin article-title 75
Mechanism of group IVA cytosolic phospholipase A(2) activation by phosphorylation
###end article-title 75
###begin article-title 76
Mechanism of regulation of group IVA phospholipase A2 activity by Ser727 phosphorylation
###end article-title 76
###begin article-title 77
Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2
###end article-title 77
###begin article-title 78
20-Hydroxyeicosatetraenoic acid mediates calcium/calmodulin-dependent protein kinase II-induced mitogen-activated protein kinase activation in vascular smooth muscle cells
###end article-title 78
###begin article-title 79
Calcium/calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-stimulated ERK activation
###end article-title 79
###begin article-title 80
cPLA2 phosphorylation at serine-515 and serine-505 is required for arachidonic acid release in vascular smooth muscle cells
###end article-title 80
###begin article-title 81
Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation
###end article-title 81
###begin article-title 82
Colocalization of the mu-opioid receptor and calcium/calmodulin-dependent kinase II in distinct pain-processing brain regions
###end article-title 82
###begin article-title 83
###xml 31 34 <span type="species:ncbi:10116">rat</span>
Localization of CaMKIIalpha in rat primary sensory neurons: increase in inflammation
###end article-title 83
###begin article-title 84
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
Signalling pathways involved in the sensitisation of mouse nociceptive neurones by nerve growth factor
###end article-title 84
###begin article-title 85
Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its vanilloid binding
###end article-title 85
###begin article-title 86
###xml 85 88 <span type="species:ncbi:10116">rat</span>
Translocation of the 85-kDa phospholipase A2 from cytosol to the nuclear envelope in rat basophilic leukemia cells stimulated with calcium ionophore or IgE/antigen
###end article-title 86
###begin article-title 87
Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum
###end article-title 87
###begin article-title 88
Critical duration of intracellular Ca2+ response required for continuous translocation and activation of cytosolic phospholipase A2
###end article-title 88
###begin article-title 89
Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes
###end article-title 89
###begin article-title 90
Cytosolic phospholipase A2-alpha associates with plasma membrane, endoplasmic reticulum and nuclear membrane in glomerular epithelial cells
###end article-title 90
###begin article-title 91
Role of p38 and p44/42 mitogen-activated protein kinases in microglia
###end article-title 91
###begin article-title 92
Neuronal Ca2+/calmodulin-dependent protein kinase II - discovery, progress in a quarter of a century, and perspective: implication for learning and memory
###end article-title 92
###begin article-title 93
Calcium-calmodulin-dependent protein kinase II contributes to spinal cord central sensitization
###end article-title 93
###begin article-title 94
Phosphatidylinositol 3-kinase is a key mediator of central sensitization in painful inflammatory conditions
###end article-title 94
###begin article-title 95
Reversal of chronic inflammatory pain by acute inhibition of Ca2+/calmodulin-dependent protein kinase II
###end article-title 95
###begin article-title 96
###xml 100 103 <span type="species:ncbi:10116">rat</span>
Ca2+/calmodulin-dependent protein kinase II in the spinal cord contributes to neuropathic pain in a rat model of mononeuropathy
###end article-title 96
###begin article-title 97
ATP receptor-operated Ca2+ influx and catecholamine release from neuronal cells
###end article-title 97
###begin article-title 98
Roles of Ca2+ influx through ATP-activated channels in catecholamine release from pheochromocytoma PC12 cells
###end article-title 98
###begin article-title 99
Dynamic control of CaMKII translocation and localization in hippocampal neurons by NMDA receptor stimulation
###end article-title 99
###begin article-title 100
Interaction with the NMDA receptor locks CaMKII in an active conformation
###end article-title 100
###begin article-title 101
Activity-driven postsynaptic translocation of CaMKII
###end article-title 101
###begin article-title 102
Calmodulin-kinases: modulators of neuronal development and plasticity
###end article-title 102
###begin article-title 103
In vivo recruitment by painful stimuli of AMPA receptor subunits to the plasma membrane of spinal cord neurons
###end article-title 103
###begin article-title 104
Ca2+/calmodulin-dependent protein kinase II potentiates ATP responses by promoting trafficking of P2X receptors
###end article-title 104
###begin article-title 105
###xml 99 102 <span type="species:ncbi:10116">rat</span>
An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat
###end article-title 105
###begin article-title 106
P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury
###end article-title 106

